Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Pharmacoeconomic analysis of the use of actovegin in patients with post-stroke cognitive impairment in the health care system of the Russian Federation

Full Text:


Post-stroke cognitive impairment (PSCI) is often characterized by a complex prognosis of neurorehabilitation, insufficient restoration of the functional status of patients, and a high risk of recurrent strokes and disability, which determines considerable health care costs. Objective: to carry out a comparative pharmacoeconomic analysis of the use of actovegin (Takeda Pharmaceuticals, Switzerland) in Russian patients with PSCI. Patients and methods. The investigation was conducted using a modeling method to determine the cost-effectiveness of competing treatment strategies: standard patient management; standard patient management and use of actovegin. Data from the ARTEMIDA clinical trial were used. Results and discussion. The use of actovegin was economically justified, which was expressed in more preferable cost-effectiveness indicators. Also, the use of actovegin in patients significantly reduced the risk of post-stroke dementia and, accordingly, the cost of treatment in future periods. Conclusion. The findings data indicate the clinical and economic feasibility of using actovegin in patients with PSCI.

About the Authors

V. V. Ryazhenov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia, Moscow
Russian Federation
Department of Regulatory Relations in the Circulation of Medicines and Medical Products

S. G. Gorokhova
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Moscow
Russian Federation

A. V. Knyazev
Takeda Pharmaceuticals, Moscow
Russian Federation


1. Борискина ВМ. Эффективность Актовегина при лечении заболеваний центральной и периферической нервной системы. Нейромышечные болезни. 2015;(2):25-31. [Boriskina LM. The effectiveness of Actovegin in the treatment of diseases of the Central and peripheral nervous system. Neiromyshechnyi bolezni. 2015;(2):25-31. (In Russ.)].

2. Евзельман МА, Александрова НА. Когнитивные нарушения у больных с ишемическим инсультом и их коррекция. Журнал неврологии и психиатрии им. Т.Т. Корсакова. 2013;(10):36-9. [Evzel’man MA, Aleksandrova NA. Cognitive impairment in patients with ischemic stroke and its correction. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2013;(10):36-9. (In Russ.)].

3. Kalaria RN, Akinyemi R, Ihara M. Stroke injury, cognitive impairment and vascular dementia. Trends Neurosci. 2009 Dec;32(12): 619-28. doi: 10.1016/j.tins.2009.07.006. Epub 2009 Sep 30.

4. Левин ОС, Васенина ЕЕ, Дударова МА, Чимагомедова АШ. Отставленное прогрессирование когнитивных нарушений после ишемического инсульта: причины и подходы к коррекции. Современная терапия в психиатрии и неврологии. 2017;(4):14-9. [Levin OS, Vasenina EE, Dudarova MA, Chimagomedova ASh. Delayed progression of cognitive impairment after ischemic stroke: causes and approaches to correction. Sovremennaya terapiya v psikhiatrii i nevrologii. 2017;(4):14-9. (In Russ.)].

5. Вахнина НВ. Профилактика и лечение постинсультных когнитивных нарушений. Эффективная фармакотерапия. Неврология и психиатрия. 2014;(4):32-9. [Vakhnina NV. Prevention and treatment of post-stroke cognitive impairment. Effektivnaya farmakoterapiya. Nevrologiya i psikhiatriya. 2014;(4):32-9. (In Russ.)].

6. Захаров ВВ, Вахнина НВ, Громова ДО, Тараповская АА. Диагностика и лечение когнитивных нарушений после инсульта. Медицинский совет. 2015;(10):14-20. [Zakharov VV, Vakhnina NV, Gromova DO, Tarapovskaya AA. Diagnosis and treatment of cognitive impairment after stroke. Meditsinskii sovet. 2015;(10):14-20. (In Russ.)].

7. Delavaran H, Jö nsson AC, Lö vkvist H, et al. Cognitive function in stroke survivors: A 10-year follow-up study. Acta Neurol Scand. 2017 Sep;136(3):187-194. doi: 10.1111/ane. 12709. Epub 2016 Nov 1.

8. Brainin M, Tuomilehto J, Heiss WD, et al. Post-stroke cognitive decline: an update and perspectives for clinical research. Eur J Neurol. 2015 Feb;22(2):229-38, e13-6. doi: 10.1111/ene. 12626. Epub 2014 Dec 9.

9. Claesson L, Lindеn T, Skoog I, Blomstrand C. Cognitive impairment after stroke-impact on activities of daily living and costs of care for elderly people. The Gö teborg 70+ Stroke Study. Cerebrovasc Dis. 2005;19(2): 102-9. Epub 2004 Dec 17.

10. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010:findings from the Global Burden of Disease Study 2010. Lancet. 2014 Jan 18;383(9913):245-54.

11. Chomova M, Zitnanova I. Look into brain energy crisis and membrane pathophysiology in ischemia and reperfusion. Stress. 2016 Jul;19(4): 341-8. doi: 10.1080/10253890.2016.1174848. Epub 2016 Apr 19.

12. Gasparova Z, Stara V, Stolc S. Effect of antioxidants on functional recovery after in vitro-induced ischemia and long-term potentiation recorded in the pyramidal layer of the CA1 area of rat hippocampus. Gen Physiol Biophys. 2014;33(1):43-52. doi: 10.4149/gpb_2013062. Epub 2013 Aug 12.

13. Bordet R, Ihl R, Korczyn AD, et al. Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report. BMC Med. 2017 May 24; 15(1):107. doi: 10.1186/s12916-017-0869-6.

14. Korczyn A, Brainin M, Guekht A. Neuroprotection in ischemic stroke: what does the future hold? Expert Rev Neurother. 2015 Mar;15(3):227-9. doi: 10.1586/14737175. 2015.1014806.

15. Reiter RJ, Tan DX, Manchester LC, Tamura H. Melatonin defeats neurally-derived free radicals and reduces the associated neuromorphological and neurobehavioral damage. J Physiol Pharmacol. 2007 Dec;58 Suppl 6:5-22.

16. Reiter R J, Tan DX, Jou MJ, et al. Biogenicamines in the reduction of oxidative stress: melatonin and its metabolites. Neuro Endocrinol Lett. 2008 Aug;29(4):391-8.

17. Meilin S, Machicao F, Elmlinger M. Treatment with Actovegin improves spatial learning and memory in rats following transient forebrain ischaemia. J Cell Mol Med. 2014 Aug;18(8):1623-30. doi: 10.1111/jcmm.12297. Epub 2014 May 6.

18. Machicao F, Muresanu DF, Hundsberger H, et al. Pleiotropic neuroprotective and metabolic effects of Actovegin’s mode of action. J Neurol Sci. 2012 Nov 15;322(1-2):222-7. doi: 10.1016/j.jns. 2012.07.069. Epub 2012 Aug 19.

19. Guekht A, Skoog I, Edmundson S, et al. ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment. Stroke. 2017 May;48(5): 1262-1270. doi: 10.1161/STROKEAHA.116. 014321.

20. Pendlebury ST. Dementia in patients hospitalized with stroke: rates, time course, and clinicopathologic factors. Int J Stroke. 2012 Oct;7(7): 570-81. doi: 10.1111/j.1747-4949.2012.00837.x. Epub 2012 Jul 11.

21. Калын ЯБ, Гаврилова СИ, Михайлова НМ. Фармакоэкономические аспекты болезни Альцгеймера. Современная терапия в психиатрии и неврологии. 2014;(2):10-5. [Kalyn YaB, Gavrilova SI, Mikhailova NM. Pharmacoeconomical aspects of Alzheimer’s disease. Sovremennaya terapiya v psikhiatrii i nevrologii. 2014;(2):10-5. (In Russ.)].


For citations:

Ryazhenov V.V., Gorokhova S.G., Knyazev A.V. Pharmacoeconomic analysis of the use of actovegin in patients with post-stroke cognitive impairment in the health care system of the Russian Federation. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(3):66-71. (In Russ.)

Views: 397

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)